Takeda's maribavir hits phase 3 goal as pharma looks forward to regulatory talks

Takeda’s experimental TAK-620 (maribavir) has hit its main phase 3 goal in helping transplant patients with refractory/resistant cytomegalovirus (CMV) infection.